Hayashi Motohiro, Chernov Mikhail F, Lipski Samuel M, Tamura Noriko, Yomo Shoji, Horiba Ayako, Tsuzuki Shyunsuke, Izawa Masahiro, Okada Yoshikazu, Muragaki Yoshihiro, Iseki Hiroshi, Ivanov Pavel, Régis Jean, Takakura Kintomo
Department of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Acta Neurochir Suppl. 2013;116:25-36. doi: 10.1007/978-3-7091-1376-9_5.
Gamma Knife surgery (GKS) should be considered a standard treatment option for small and medium-sized vestibular schwannomas (VSs). It results in a tumor control rate similar to that seen with microsurgery and provides better preservation of facial nerve function and hearing.
From December 2002 to April 2011, a total of 260 patients with VS underwent GKS using Leksell Gamma Knife model 4C with an automatic positioning system. There were 30 Koos stage I tumors, 112 stage II, 100 stage III, and 18 stage IV. All patients were treated with the use of high-resolution magnetic resonance imaging; creation of the highly precise conformal and selective multi-isocenter dose planning with small collimators, carefully sparing adjacent cranial nerves of any excessive irradiation; and creation of a wide 80 % isodose area within the tumor while applying a low marginal dose (mean 11.9 Gy) at the 50 % isodose line.
Among 182 patients who were followed for more than 3 years after treatment, the tumor control and shrinkage rates were 98.4 % and 76.4 %, respectively. Volume reduction of >50 % was marked in 54.9 % of VSs. Preservation of facial nerve function and hearing at the pretreatment level was noted in 97.8 % and 87.9 %, respectively. There was marked improvement of facial nerve function and hearing after GKS in 2.2 % and 3.8 %, respectively. There was no major morbidity.
Due to contemporary technological and methodological achievements GKS can be focused not only on growth control but on shrinking the VS, with possible reversal of the neurological deficit.
伽玛刀手术(GKS)应被视为中小型前庭神经鞘瘤(VS)的标准治疗选择。其肿瘤控制率与显微手术相似,且能更好地保留面神经功能和听力。
2002年12月至2011年4月,共有260例VS患者使用带有自动定位系统的Leksell伽玛刀4C型接受了GKS治疗。其中有30例Koos I期肿瘤、112例II期、100例III期和18例IV期。所有患者均接受高分辨率磁共振成像检查;使用小准直器创建高精度的适形和选择性多等中心剂量规划,小心避免对相邻颅神经的过度照射;在肿瘤内创建80%的宽等剂量区域,同时在50%等剂量线处应用低边缘剂量(平均11.9 Gy)。
在治疗后随访超过3年的182例患者中,肿瘤控制率和缩小率分别为98.4%和76.4%。54.9%的VS体积缩小超过50%。分别有97.8%和87.9%的患者面神经功能和听力保留在治疗前水平。GKS后分别有2.2%和3.8%的患者面神经功能和听力有明显改善。无严重并发症。
由于当代技术和方法的成就,GKS不仅可以专注于控制肿瘤生长,还可以使VS缩小,并可能逆转神经功能缺损。